

Neuropsychiatric Effects of COVID

John E. Fanning, MD, FACP
Regional Chair of Internal Medicine
UAB School of Medicine - Huntsville

Objectives

1. Pathophysiology of Neuropsychiatric Effects of Acute COVID-19
2. Neuropsychiatric manifestations in
 - COVID-19
 - Post-acute COVID-19 syndrome (PACS) “Long COVID”

On Tuesday, January 28, 1986, at 11:39 AM EST, the Space Shuttle *Challenger* broke apart 73 seconds into its flight, killing all seven crew members aboard

The **fall of the Berlin Wall** on Thursday, November 9, 1989, during the Peaceful Revolution, was a pivotal event in world history.

The first impact was that of American Airlines Flight 11, which crashed into the North Tower of the World Trade Center complex in Lower Manhattan at 08:46. Sixteen minutes later, at 09:03, the World Trade Center's South Tower was hit by United Airlines Flight 175


On Wednesday, March 11, 2020, the WHO declared the SARS-CoV 2 outbreak to be a pandemic

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19)

COVID-19 was initially thought to be primarily a respiratory disease, sometimes leading to viral pneumonia.

It is now recognized as a complex disorder affecting many body systems.

“He who knows syphilis knows medicine”



- Sir William Osler

Sir William Osler (1849 –1919)

Considered the “Father of Modern Medicine”

One of the "greatest diagnosticians ever to wield a stethoscope".

First Physician-in-Chief of the new Johns Hopkins Hospital 1889

Established the full-time, sleep-in residency system

Staff physicians lived in the administration building of the hospital.

Residency was open-ended, and long tenure was the rule.

Physicians spent as long as seven or eight years as residents, during which time they led a restricted, almost monastic life.

Sir William Osler

"Listen to your patient; he is telling you the diagnosis"

"Pneumonia is the friend of the aged."

"He who studies medicine without books sails an uncharted sea, but he who studies medicine without patients does not go to sea at all."

"I desire no other epitaph than the statement that I taught medical students in the wards, as I regard this as by far the most useful and important work, I have been called upon to do."


SARS-CoV-2 (COVID-19)

WHO Data

As of 18 June 2023, over 768 million confirmed cases and over 6.9 million deaths have been reported globally.

OSU.EDU

Help BuckeyeLink Map Find People Webmail Search Ohio State



SEARCH NEWS

Twitter Facebook YouTube

 OHIO STATE NEWS

Campus
Science & Medicine
Arts & Humanities
The Conversation
Sports
COVID-19
Newsletter
Key Issues

SUBSCRIBE

Sign up to receive the latest news about The Ohio State University in your inbox.

Feb 23, 2021

More than 87,000 scientific papers on coronavirus since pandemic

Study finds "astonishing" growth even as partnerships shrink



Key Issues

Sign up to receive the latest news about The Ohio State University in your inbox.

More than **87,000** scientific papers on coronavirus since pandemic

Study finds “astonishing” growth even as partnerships shrink



Key Issues

Sign up to receive the latest news about The Ohio State University in your inbox.


More than 87,000 scientific papers on coronavirus since pandemic

Study finds "astonishing" growth even as partnerships shrink


SARS-CoV-2 spike protein binds to ACE2 receptor

ACE2 receptor


Viral entry and replication



dos Santos, et al Biomedicine & Pharmacotherapy, Volume 129, 2020,



Victor J., et al, SARS-CoV-2 infection: The role of cytokines in COVID-19 disease, Cytokine & Growth Factor Reviews, Volume 54, 2020




Victor J., et al, SARS-CoV-2 infection: The role of cytokines in COVID-19 disease, Cytokine & Growth Factor Reviews, Volume 54, 2020


“Happy Hypoxemia”

“Happy Hypoxemia”


NEJM 2020: 1099 hospitalized COVID-19 patients only 18.7%
reported dyspnea despite low $\text{PaO}_2/\text{FiO}_2$

Guan, et al, Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020







The pathophysiology of 'happy' hypoxemia in COVID-19 Dhont et al. *Respiratory Research* (2020) 21:198




The pathophysiology of 'happy' hypoxemia in COVID-19 Dhont et al. *Respiratory Research* (2020) 21:198




The pathophysiology of 'happy' hypoxemia in COVID-19 Dhont et al. *Respiratory Research* (2020) 21:198




The pathophysiology of 'happy' hypoxemia in COVID-19 Dhont et al. *Respiratory Research* (2020) 21:198



The pathophysiology of 'happy' hypoxemia in COVID-19 Dhont et al. *Respiratory Research* (2020) 21:198




The pathophysiology of 'happy' hypoxemia in COVID-19 Dhont et al. *Respiratory Research* (2020) 21:198



The pathophysiology of 'happy' hypoxemia in COVID-19 Dhont et al. Respiratory Research (2020) 21:198

"Happy Hypoxemia"



<https://www.biosciencenotes.com/oxyhemoglobin-dissociation-curve/>

"Happy Hypoxemia"









Fig. 2 Mechanisms of hypoxemia in COVID-19







Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neurol Sci* **41**, 2353–2366 (2020)




Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neurol Sci* **41**, 2353–2366 (2020)




Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neurol Sci* **41**, 2353–2366 (2020)




Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neuro Sci* **41**, 2353–2366 (2020)




Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neuro Sci* **41**, 2353–2366 (2020)




Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neuro Sci* **41**, 2353–2366 (2020)




Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neurol Sci* **41**, 2353–2366 (2020)



Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neurol Sci* **41**, 2353–2366 (2020)



Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neurol Sci* **41**, 2353–2366 (2020)



Orsini, A., Corsi, M., Santangelo, A. et al. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. *Neurol Sci* **41**, 2353–2366 (2020)

COVID Coagulopathy

From benign skin lesions on the feet (e.g., COVID toe), to life-threatening thrombotic events, the SARS-CoV-2 virus has high prevalence of deadly blood clots.

Early studies have shown that approximately 25-70 percent — of critically ill patients have a confirmed venous thromboembolism (VTE)

Approximately 70 percent of COVID-19 patients who died met criteria for disseminated intravascular coagulation (DIC)

Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation *Molecular mlo-online.com*






Figure 2. The impact of SARS-CoV-2 infection on Virchow's triad of thrombosis


Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation *Molecular mlo-online.com*




Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com




Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com




Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com




Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com




Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com



Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com



Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com



Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com

Laboratory Coagulation Parameter	Change in COVID-19	Indication
D-dimer	↑↑	Increased clot formation
Prothrombin time	↑	Unbalanced extrinsic coagulation
Fibrinogen	↑ (acute phase) ↓ (DIC phase)	Inflammation DIC
Platelet count	↓/↑	Increased platelet consumption
Von Willebrand Factor (VWF)	↑↑	Endothelial dysfunction and platelet activation
Coagulation Factor VIII	↑↑	Thrombotic risk
Plasminogen Activator Inhibitor-1 (PAI-1)	↑↑	Endothelial dysfunction/fibrinolysis shutdown
Prothrombin fragment 1+2	↑↑	Increased clot formation
Soluble thrombomodulin	↑↑	Endothelial dysfunction/decreased anticoagulant activity of endothelium

Table 1. Significantly altered laboratory parameters of coagulation and their indication in COVID-19

Dahler, et al. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation Molecular mlo-online.com

COVID-19 Acute Neurological Complications

- Encephalopathy
- Encephalitis
- Acute Demyelinating Encephalomyelitis
- Stroke
- Guillain-Barré syndrome

Brown , et al. Pathophysiology, diagnosis, and management of neuroinflammation in covid-19 *BMJ* 2023

GCS-Neuro-COVID Study


28 centers, 13 countries,
Documented Neurological Manifestations

- Headache (37%)
- Anosmia or ageusia (26%)
- Acute encephalopathy (49%)
- Coma (17%)
- Stroke (6%)
- Meningitis/encephalitis (0.5%)

GCS-Neuro-COVID Consortium and the ENERGY Consortium. JAMA Netw Open 2021

...COVID-19 delirium is associated with autoimmune encephalitis, post-ARDS brain dysfunction caused by systemic hyperinflammation and neuroinflammation associated with COVID-19 ...multiple strokes caused by abnormal blood clotting, microthrombosis, and extensive cerebral infarction

COVID-19 patients who left the ICU after intubation showed cognitive decline at the rate of 46.6% at approximately 6 months (as compared to 31.8% in non-COVID patients) and 53.1% at approximately 1 year




Kyohei, et al COVID-19 delirium and encephalopathy: Pathophysiology assumed in the first 3 years of the ongoing pandemic, Brain Disorders, Volume 10, 2023,

The Lancet 2021

6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records

Taquet M, et al. Lancet Psychiatry. 2021 May;8(5):416-427

Incidence of Major Outcomes after COVID-19 vs Respiratory Infections






Incidence of major outcomes after COVID-19

Hospitalisation vs No Hospitalisation

Encephalopathy vs No Encephalopathy


— Encephalopathy — Hospitalisation
 Matched cohort without encephalopathy Matched cohort without hospitalisation





A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic


	Pooled	Follow up			Severity			Age		Sex		Region Income		
		<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	≥60 years	Male <50%	Male ≥50%	High	Middle-Low	
Psychiatric	Any psychiatric symptoms	19.7	23.6	20.1	18.0	9.4	18.2	20.8	17.9	26.0	14.9	23.0	22.2	13.4
	Depression	18.3	18.8	19.8	12.4	14.7	16.8	10.2	18.3	18.2	16.4	19.7	18.7	16.0
	PTSD	17.9	23.1 ⁺	16.2	7.4	NA	14.3	22.4	15.4	24.3	10.6 ⁺	20.5	18.8	13.3
	Anxiety	16.2	18.9	13.7	15.4	28.5 ⁺	20.7	12.9	17.2	13.5	14.5	18.5	17.3	12.9
	Sleep disturbance	13.5	9.1	19.3	12.3	0.7 ⁺	10.9	21.8	10.9	23.0	10.5	16.8	16.5	8.3



Zeng, N, et al *Mol Psychiatry* 28, 423–433 (2023).

A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic


		Pooled	Follow Up 6-12 Months				Severity			Age		Sex		Region Income	
			<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	≥60 years	Male <50%	Male ≥50%	High	Middle-Low	
Psychiatric	Any psychiatric symptoms	19.7	23.6	20.1	18.0	9.4	18.2	20.8	17.9	26.0	14.9	23.0	22.2	13.4	
	Depression	18.3	18.8	19.8	12.4	14.7	16.8	10.2	18.3	18.2	16.4	19.7	18.7	16.0	
	PTSD	17.9	23.1 [*]	16.2	7.4	NA	14.3	22.4	15.4	24.3	10.6 [*]	20.5	18.8	13.3	
	Anxiety	16.2	18.9	13.7	15.4	28.5 [*]	20.7	12.9	17.2	13.5	14.5	18.5	17.3	12.9	
	Sleep disturbance	13.5	9.1	19.3	12.3	0.7 [*]	10.9	21.8	10.9	23.0	10.5	16.8	16.5	8.3	



Zeng, N, et al *Mol Psychiatry* 28, 423–433 (2023).

A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic


	Pooled	Follow up			Severity			Age		Sex		Region Income		
		<3 Months	3-6 Months	6-12 Months	Asymptomatic/Mild	Severe/Critical		<65 years	≥60 years	Male <50%	Male ≥50%	High	Middle-Low	
Psychiatric	Any psychiatric symptoms	19.7	23.6	20.1	18.0	9.4	18.2	20.8	17.9	26.0	14.9	23.0	22.2	13.4
	Depression	18.3	18.8	19.8	12.4	14.7	16.8	10.2	18.3	18.2	16.4	19.7	18.7	16.0
	PTSD	17.9	23.1 ⁺	16.2	7.4	NA	14.3	22.4	15.4	24.3	10.6 ⁺	20.5	18.8	13.3
	Anxiety	16.2	18.9	13.7	15.4	28.5 ⁺	20.7	12.9	17.2	13.5	14.5	18.5	17.3	12.9
	Sleep disturbance	13.5	9.1	19.3	12.3	0.7 ⁺	10.9	21.8	10.9	23.0	10.5	16.8	16.5	8.3



Zeng, N, et al *Mol Psychiatry* 28, 423–433 (2023).

A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic


	Pooled	Follow up			Severity			Age		Sex		Region Income		
		<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild	Severe/Critical	<65 years	≥60 years	Male <50%	Male ≥50%	High	Middle-Low	
Psychiatric	Any psychiatric symptoms	19.7	23.6	20.1	18.0	9.4	18.2	20.8	17.9	26.0	14.9	23.0	22.2	13.4
	Depression	18.3	18.8	19.8	12.4	14.7	16.8	10.2	18.3	18.2	16.4	19.7	18.7	16.0
	PTSD	17.9	23.1 ⁺	16.2	7.4	NA	14.3	22.4	15.4	24.3	10.6 ⁺	20.5	18.8	13.3
	Anxiety	16.2	18.9	13.7	15.4	28.5 ⁺	20.7	12.9	17.2	13.5	14.5	18.5	17.3	12.9
	Sleep disturbance	13.5	9.1	19.3	12.3	0.7 ⁺	10.9	21.8	10.9	23.0	10.5	16.8	16.5	8.3



Zeng, N, et al *Mol Psychiatry* 28, 423–433 (2023).

A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic

Psychiatric		Pooled	Follow up			Severity			Age	Sex		Region Income		
			<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	>60 years	Male <50%	Male ≥50%	High	Middle-Low
	Any psychiatric symptoms	19.7	23.6	20.1	18.0	9.4	18.2	20.8	17.9	26.0	14.9	23.0	22.2	13.4
	Depression	18.3	18.8	19.8	12.4	14.7	16.8	10.2	18.3	18.2	16.4	19.7	18.7	16.0
	PTSD	17.9	23.1 ⁺	16.2	7.4	NA	14.3	22.4	15.4	24.3	10.6 ⁺	20.5	18.8	13.3
	Anxiety	16.2	18.9	13.7	15.4	28.5 ⁺	20.7	12.9	17.2	13.5	14.5	18.5	17.3	12.9
	Sleep disturbance	13.5	9.1	19.3	12.3	0.7 ⁺	10.9	21.8	10.9	23.0	10.5	16.8	16.5	8.3



Zeng, N, et al *Mol Psychiatry* 28, 423–433 (2023).

A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic

		Pooled	Follow up			Severity			Age		Male <50%	>50% Male	Region Income	
			<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	≥60 years			High	Middle-Low
Psychiatric	Any psychiatric symptoms	19.7	23.6	20.1	18.0	9.4	18.2	20.8	17.9	26.0	14.9	23.0	22.2	13.4
	Depression	18.3	18.8	19.8	12.4	14.7	16.8	10.2	18.3	18.2	16.4	19.7	18.7	16.0
	PTSD	17.9	23.1 ⁺	16.2	7.4	NA	14.3	22.4	15.4	24.3	10.6 ⁺	20.5	18.8	13.3
	Anxiety	16.2	18.9	13.7	15.4	28.5 ⁺	20.7	12.9	17.2	13.5	14.5	18.5	17.3	12.9
	Sleep disturbance	13.5	9.1	19.3	12.3	0.7 ⁺	10.9	21.8	10.9	23.0	10.5	16.8	16.5	8.3

Neuropsychiatric symptoms(%)



Zeng, N, et al *Mol Psychiatry* 28, 423–433 (2023).

A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic

		Pooled	Follow up			Severity			Age		Sex		High	Income
		<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	≥60 years	Male <50%	Male ≥50%			
Psychiatric	Any psychiatric symptoms	19.7	23.6	20.1	18.0	9.4	18.2	20.8	17.9	26.0	14.9	23.0	22.2	13.4
	Depression	18.3	18.8	19.8	12.4	14.7	16.8	10.2	18.3	18.2	16.4	19.7	18.7	16.0
	PTSD	17.9	23.1 ⁺	16.2	7.4	NA	14.3	22.4	15.4	24.3	10.6 ⁺	20.5	18.8	13.3
	Anxiety	16.2	18.9	13.7	15.4	28.5 ⁺	20.7	12.9	17.2	13.5	14.5	18.5	17.3	12.9
	Sleep disturbance	13.5	9.1	19.3	12.3	0.7 ⁺	10.9	21.8	10.9	23.0	10.5	16.8	16.5	8.3

Neuropsychiatric symptoms(%)






Zeng, N, et al *Mol Psychiatry* 28, 423–433 (2023).


		Pooled	Follow up			Severity			Age		Sex		Region Income	
			<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	≥60 years	Male <50%	Male ≥50%	High	Middle-Low
Neurological	Any neurological symptoms	18.7	22.0 ⁺	22.5	15.8	12.2	12.0	13.5	20.2	17.5	18.2	19.6	20.7 ⁺	12.8
	Cognitive deficits	19.7	14.4	18.6	22.2	NA	NA	NA	20.7	9.9	17.1	17.3	14.3 ⁺	38.4
	Memory impairment	17.5	28.5	28.0	8.1	37.5 ⁺	17.4	16.9	20.3	10.0	20.2	15.5	19.5	13.4
	Loss of taste or smell	15.7	20.2	9.1	17.1	NA	NA	NA	17.0	12.5	13.8	26.7	18.1 ⁺	7.0
	Olfactory dysfunction	15.1	13.6	16.3	15.8	10.5	5.3	9.7	17.4 ⁺	8.4	23.2	10.8	16.1	12.1
	Concentration impairment	12.6	8.3	20.3	10.1	NA	17.4	18.8	12.9	NA	8.9 ⁺	30.6	15.3 ⁺	1.0
	Headache	11.5	13.1	10.9	9.5	2.6	4.2	0.7	12.9	6.1	12.8	9.7	13.0	9.1
	Gustatory dysfunction	10.6	14.0	8.1	10.0	6.6	4.9	14.5	11.4	8.5	13.5	8.7	13.1 ⁺	3.2
	Dizziness	9.7	3.8	10.7	19.5	NA	NA	NA	6.8 ⁺	73.7	7.5	17.6	18.1 ⁺	2.5
	Visual disturbance	4.7	4.2	5.7	7.7	NA	NA	NA	4.7	4.5	4.4	5.0	4.5	4.7

Neuropsychiatric symptoms(%)






	Pooled	Follow up			Severity			Age		Sex		Region Income		
		<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	≥60 years	Male <50%	Male ≥50%	High	Middle-Low	
Neurological	Any neurological symptoms	18.7	22.0 *	22.5	15.8	12.2	12.0	13.5	20.2	17.5	18.2	19.6	20.7 *	12.8
	Cognitive deficits	19.7	14.4	18.6	22.2	NA	NA	NA	20.7	9.9	17.1	17.3	14.3 *	38.4
	Memory impairment	17.5	28.5	28.0	8.1	37.5 *	17.4	16.9	20.3	10.0	20.2	15.5	19.5	13.4
	Loss of taste or smell	15.7	20.2	9.1	17.1	NA	NA	NA	17.0	12.5	13.8	26.7	18.1 *	7.0
	Olfactory dysfunction	15.1	13.6	16.3	15.8	10.5	5.3	9.7	17.4 *	8.4	23.2	10.8	16.1	12.1
	Concentration impairment	12.6	8.3	20.3	10.1	NA	17.4	18.8	12.9	NA	8.9 *	30.6	15.3 *	1.0
	Headache	11.5	13.1	10.9	9.5	2.6	4.2	0.7	12.9	6.1	12.8	9.7	13.0	9.1
	Gustatory dysfunction	10.6	14.0	8.1	10.0	6.6	4.9	14.5	11.4	8.5	13.5	8.7	13.1 *	3.2
	Dizziness	9.7	3.8	10.7	19.5	NA	NA	NA	6.8 *	73.7	7.5	17.6	18.1 *	2.5
	Visual disturbance	4.7	4.2	5.7	7.7	NA	NA	NA	4.7	4.5	4.4	5.0	4.5	4.7



	Pooled	Follow up			Severity			Age		Sex		Region Income		
		<3 Months	3-6 Months	6-12 Months	Asymptomatic	Mild/Moderate	Severe/Critical	<60 years	≥60 years	Male <50%	Male ≥50%	High	Middle-Low	
Neurological	Any neurological symptoms	18.7	22.0 *	22.5	15.8	12.2	12.0	13.5	20.2	17.5	18.2	19.6	20.7 *	12.8
	Cognitive deficits	19.7	14.4	18.6	22.2	NA	NA	NA	20.7	9.9	17.1	17.3	14.3 *	38.4
	Memory impairment	17.5	28.5	28.0	8.1	37.5 *	17.4	16.9	20.3	10.0	20.2	15.5	19.5	13.4
	Loss of taste or smell	15.7	20.2	9.1	17.1	NA	NA	NA	17.0	12.5	13.8	26.7	18.1 *	7.0
	Olfactory dysfunction	15.1	13.6	16.3	15.8	10.5	5.3	9.7	17.4 *	8.4	23.2	10.8	16.1	12.1
	Concentration impairment	12.6	8.3	20.3	10.1	NA	17.4	18.8	12.9	NA	8.9 *	30.6	15.3 *	1.0
	Headache	11.5	13.1	10.9	9.5	2.6	4.2	0.7	12.9	6.1	12.8	9.7	13.0	9.1
	Gustatory dysfunction	10.6	14.0	8.1	10.0	6.6	4.9	14.5	11.4	8.5	13.5	8.7	13.1 *	3.2
	Dizziness	9.7	3.8	10.7	19.5	NA	NA	NA	6.8 *	73.7	7.5	17.6	18.1 *	2.5
	Visual disturbance	4.7	4.2	5.7	7.7	NA	NA	NA	4.7	4.5	4.4	5.0	4.5	4.7



Anxiety and Depression

Adults- Meta-analysis of 43 large studies prevalence of anxiety in the general population during the COVID-19 outbreak is 25% (95% CI 21%–29%).

Santabábara J, et al Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul

Pediatrics - Pooled estimates obtained in the first year of the COVID-19 pandemic suggest that 1 in 4 youth globally are experiencing clinically elevated depression symptoms, while 1 in 5 youth are experiencing clinically elevated anxiety symptoms. These pooled estimates, which increased over time, are double of pre-pandemic estimates.

Racine N, et al JAMA Pediatr. 2021 Nov

Depression, anxiety, and post-traumatic stress disorder are the most often reported psychological problems in the literature (Yuan et al., 2021).

Some research found a rise in spousal violence and child abuse during the first weeks of lockdown (Fegert et al., 2020).

COVID-19 lockout potentially influenced children and that family and community participation could prevent potential mental and physical health difficulties. These children's increased psychological symptoms may be due to a lack of assistance during such a stressful period (Jiao et al., 2020)

Taukeni Acceleration of the Biopsychosocial Model in Public Health, Chapter 3, Feb 2023

Child telepsychiatry and psychotherapy advanced dramatically during this period, and the health-care system recognized and responded to these new types of care (Fegert et al., 2020).

It should be highlighted, however, that the effects of COVID-19 were not only psychological, but also social, economic, health, political, educational, labor and employment, ethnic-racial, freedom, and citizenship rights. These consequences are inextricably intertwined, resulting in socioeconomic disparities and injustices (Ferreira et al., 2020).

Taukeni Acceleration of the Biopsychosocial Model in Public Health, Chapter 3, Feb 2023

Regardless of their detrimental consequences on the person, anxiety, panic, and fear of infection have always been shown to encourage people to follow social distancing rules. On the other side, persons experiencing similar psychological changes have seen a significant rise in the incidence of accidental accidents and suicides over time. (Holingue et al., 2020).

Taukeni Acceleration of the Biopsychosocial Model in Public Health, Chapter 3, Feb 2023

Pandi-Perumal SR, et al, Alpha Psychiatry Jul 2022

www.thelancet.com/respiratory Published online September 22, 2023 [https://doi.org/10.1016/S2213-2600\(23\)00262-X](https://doi.org/10.1016/S2213-2600(23)00262-X)

C-MORE Study

Sep 22, 2023

Our study demonstrates the substantial burden of multiorgan abnormalities in patients after hospitalisation for COVID-19, with nearly one in three patients having an excess burden of multiorgan injury.

Multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment after hospitalisation.

www.thelancet.com/respiratory Published online September 22, 2023 [https://doi.org/10.1016/S2213-2600\(23\)00262-X](https://doi.org/10.1016/S2213-2600(23)00262-X)

C-MORE Study Brain Results

White matter hyperintensities and small vessel disease were more common among (COVID) patients, who also had smaller grey matter volumes relative to controls in areas for:

Higher cognitive function, including memory and emotional processing and autonomic nervous function (hippocampus, amygdala, cerebellum, and thalamic nuclei),

Motor control (bilateral putamen),

Audiovisual processing (bilateral middle temporal gyrus),

Visual processing (bilateral cuneal and intracalcarine cortex)

Wakefulness or consciousness, and

Thermoregulation (thalamic nuclei).

Spatial memory formation (left posterior cingulate cortex),

Language processing and perception (supramarginal cortex),

Pain perception (insula).

Brain MRI abnormalities were more common among patients even after excluding patients who were critically ill with COVID-19.

COVID Long Hauler

~~COVID Long Hauler~~

~~Long COVID~~

~~COVID Long Hauler~~

~~Long COVID~~

Post-acute sequelae of SARS-CoV-2 infection (PASC)

Post-acute sequelae of SARS-CoV-2 infection (PASC)

Defined as ongoing, relapsing, or new symptoms or conditions present 30 or more days after infection

Short- and long-term effects of PASC have substantial impacts on health-related quality of life, earnings, and health care costs


Defining PASC precisely is difficult because it is heterogeneous, composed of conditions with variable and potentially overlapping etiologies (eg, organ injury, viral persistence, immune dysregulation, autoimmunity, and gut dysbiosis)

Thaweethai et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023;329(22):1934–1946.

What percentage of adults ever had Long COVID or currently have Long COVID, and did it differ by sex?


- In 2022, 6.9% of adults ever had Long COVID and 3.4% of adults currently had Long COVID (Figure 1).

Figure 1. Percentage of adults who ever had Long COVID or currently have Long COVID, by sex: United States, 2022




NCHS Data Brief No. 480 September 2023

Figure 2. Percentage of adults who ever had Long COVID or currently have Long COVID, by age group: United States, 2022




NCHS Data Brief No. 480 September 2023

Figure 3. Percentage of adults who ever had Long COVID or currently have Long COVID, by race and Hispanic origin: United States, 2022




NCHS Data Brief No. 480 September 2023

Figure 4. Percentage of adults who ever had Long COVID or currently have Long COVID, by family income as a percentage of the federal poverty level: United States, 2022





NCHS Data Brief No. 480 September 2023

Figure 5. Percentage of adults who ever had Long COVID or currently have Long COVID, by urbanization level: United States, 2022



NCHS Data Brief No. 480 September 2023






In a meta-analysis, fatigue was found in 32% and cognitive impairment was found in 22% of patients with COVID-19 at 12 weeks after infection ¹.

Cognitive impairments in long COVID are debilitating, at the same magnitude as intoxication at the UK drink driving limit or 10 years of cognitive ageing ²

1 Ceban, et al Brain Behav Immun. 2022 Mar;101:93-135


2 Holdsworth, et al PLoS One. 2022 Jun 10;17(6)

Theories on Pathophysiology of Long COVID



Theories on Pathophysiology of Long COVID


Microbiota dysbiosis



Impacts of SARS-CoV-2 on the microbiota and virome (including SARS-CoV-2 persistence)

Theories on Pathophysiology of Long COVID


Autoimmunity and immune priming



Autoimmunity and primed immune cells from molecular mimicry

Theories on Pathophysiology of Long COVID

Blood clotting and endothelial abnormalities



Microvascular blood clotting with endothelial dysfunction


Theories on Pathophysiology of Long COVID



Long COVID is associated with extensive in-vivo neuroinflammation on [^{18}F]DPA-714 PET

(MS related isotope)

Visser, et al medRxiv 2022



Hamster models exhibited an ongoing inflammatory state involving T cell and myeloid activation, production of pro-inflammatory cytokines, and an interferon response that was correlated with anxiety and depression-like behaviours in the hamsters, with similar transcriptional signatures found in the tissue of humans who had recovered from COVID-19

Frere et al, Sci Transl Med. 2022 Sep

Long COVID Working Case Definition – NIH

More than 200 symptoms are associated with long COVID.

“Long COVID is not just one syndrome; it's a syndrome of syndromes”

- Post-exertional malaise
- Fatigue
- Brain fog
- Dizziness
- Gastrointestinal symptoms
- Palpitations
- Changes in sexual desire or capacity
- Loss of or change in smell or taste
- Thirst
- Chronic cough
- Chest pain
- Abnormal movements

Thaweethai et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023;329(22):1934–1946.

Long COVID Working Case Definition - NIH

Four Clusters

Cluster 1 loss of or change in smell or taste

Cluster 2 by post-exertional malaise and fatigue

Cluster 3 by brain fog, post-exertional malaise, and fatigue

Cluster 4 by fatigue, post-exertional malaise, dizziness, brain fog, gastrointestinal symptoms, and palpitations

Long COVID more common and more severe manifestations in people infected **before** Omicron.

NIH RECOVER Initiative

RECOVER-NEURO - web-based training program called BrainHQ and transcranial direct current stimulation

RECOVER-VITAL - SARS-CoV-2 persistence; up to 25 days nirmatrelvir/ritonavir (Paxlovid)

RECOVER-SLEEP - melatonin and sleep coaching

RECOVER-AUTONOMIC - postural orthostatic tachycardia syndrome (POTS)

Summary

COVID-19 Pandemic has had widespread pathophysiologic effects across the world, with multi-organ involvement

Neurologic after-effects appear to be long-lasting and variable

Psychologic pathology has both physiologic and emotional basis from the trauma of the lockdowns and response

I want to be more like Sir William Osler or at least have that mustache

Questions?

